G
Guido Bold
Researcher at Novartis
Publications - 115
Citations - 3947
Guido Bold is an academic researcher from Novartis. The author has contributed to research in topics: Tyrosine kinase & Alkyl. The author has an hindex of 33, co-authored 115 publications receiving 3839 citations.
Papers
More filters
Journal ArticleDOI
Tyrosine kinase inhibitors: From rational design to clinical trials
Peter Traxler,Guido Bold,Elisabeth Buchdunger,Giorgio Caravatti,Pascal Furet,Paul W. Manley,Terence O'reilly,Jeanette Marjorie Wood,Juerg Zimmermann +8 more
TL;DR: Three successful examples of drug design at Novartis using a tyrosine kinase as a molecular target are described and promising data from phase I and II clinical trials in CML patients support the fact that the STI571 represents a new treatment modality for CML.
Patent
Pyrrolopyrimidines and processes for the preparation thereof
TL;DR: In this paper, 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula (I) were described and the symbols are as defined in claim 1.
Journal ArticleDOI
Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
Peter Traxler,Guido Bold,Joerg Frei,Marc Lang,Nicholas B. Lydon,Helmut Mett,Elisabeth Buchdunger,Thomas Meyer,Marcel Mueller,Pascal Furet +9 more
TL;DR: 4-(Phenylamino)-1H-pyrazolo[3,4-d]pyrimidines represent a new class of highly potent tyrosine kinase inhibitors which preferentially inhibit the EGF-mediated signal transduction pathway and have the potential for further evaluation as anticancer agents.
Patent
Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
Andreas Floersheimer,Pascal Furet,Paul W. Manley,Guido Bold,Eugen Boss,Vito Guagnano,Andrea Vaupel +6 more
TL;DR: In this paper, the use of diaryl urea derivatives in the treatment of protein kinase dependent diseases or for the manufacture of pharmaceutical compositions for use in the treatments of said diseases was discussed.
Journal ArticleDOI
New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis
Guido Bold,Karl-Heinz Altmann,Jorg Frei,Marc Lang,Paul W. Manley,Peter Dr Traxler,Wietfeld Bernhard,Josef Brüggen,Elisabeth Buchdunger,Robert Cozens,Stefano Ferrari,Pascal Furet,Francesco Hofmann,Georg Martiny-Baron,Jürgen Mestan,Johannes Rösel,Matthew A. Sills,David R. Stover,Figan Acemoglu,Eugen Boss,Emmenegger R,Lasser L,Masso E,Roth R,Schlachter C,Vetterli W +25 more
TL;DR: Modification of the 1-anilino moiety afforded derivatives with higher selectivity for the VEGF receptor tyrosine kinases Flt-1 and KDR compared to the related receptors PDGF-R and c-Kit.